Gilead Sciences Inc
Gilead Sciences Inc price
About Gilead Sciences Inc
Gilead Sciences, Inc. on globaali biolääkeyritys, jonka toiminnot kattavat Yhdysvallat, Euroopan ja lukuisat kansainväliset markkinat. Sen ydintehtävänä on löytää, kehittää ja kaupallistaa innovatiivisia lääkkeitä vastaamaan kriittisiin terveydenhuollon tarpeisiin. Yrityksen laaja tuotevalikoima sisältää hoitoja moniin vakaviin sairauksiin. HIV/AIDS:n osalta se toimittaa keskeisiä hoitoja, kuten Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild ja Atripla. Vuoden 2019 koronaviruspandemian vastauksena Gilead tarjoaa Vekluryä, suonensisäisesti annettavaa injektoitavaa lääkettä. Sen maksasairauksien hoitoon tarkoitetut tuotteet sisältävät Epclusan, Harvonin, Vosevin, Vemlidyn ja Vireadin. Lisäksi Gilead tukee potilaita, jotka kamppailevat hematologisten sairauksien, erilaisten syöpien ja soluterapian kanssa, tuotteilla kuten Yescarta, Tecartus, Trodelvy ja Zydelig. Muita erikoislääkkeitä ovat Letairis, suun kautta otettava lääke keuhkovaltimopaineen hoitoon; Ranexa, myös suun kautta otettava lääke krooniseen anginaan; sekä AmBisome, liposomaalinen valmiste vakavien invasiivisten sienitulehdusten torjuntaan. Gilead Sciences, Inc. tekee aktiivisesti yhteistyösopimuksia monipuolisten kumppaneiden kanssa edistääkseen terapeuttista tuoteputkeaan. Näihin kuuluvat Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc. ja Merck & Co, Inc. Yritys perustettiin vuonna 1987, ja sen pääkonttori sijaitsee Foster Cityssä, Kaliforniassa.
- Osaketunnus
- GILD
- Yritys
- Gilead Sciences, Inc.
- Teollisuus
- Terveydenhuolto
- Kategoria
- US
- Osakeanti / osakeyhdistäminen
- 12
- Lanseerauspäivä
- 22.1.1992
- Listattu pörssi
- NASDAQ
Taloustiedot
Yhteenveto: GILD reported Revenue of 8.30B (+6,83 %), beating expectations; EPS of 2,55 (+3,24 %), beating expectations.
Osingot
Gilead Sciences Inc conversion tables
 |  |
|---|---|
| 0.5 GILD | 74,52 EUR |
| 1 GILD | 149,04 EUR |
| 5 GILD | 745,24 EUR |
| 10 GILD | 1 490,49 EUR |
| |
|---|---|
| 0.5 EUR | 0,0033546 GILD |
| 1 EUR | 0,0067092 GILD |
| 5 EUR | 0,033546 GILD |
| 10 EUR | 0,067092 GILD |
More to explore
FAQ
GILD is trading at €149,05, −4,28 % over the last 24 hours. Track live moves on the price chart at the top of this page.
The GILD stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. GILD is currently trading at €149,05, −4,28 % over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on GILD price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the Terveydenhuolto sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.
P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. GILD's P/E ratio is currently -- — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from GILD; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against GILD's historical range and other companies in the Terveydenhuolto sector.
Gilead Sciences, Inc.'s market cap is currently 194,61 mrd. EUR. Market cap is calculated as stock price × total shares outstanding.
Disclaimer
The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.
OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.